| CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms RV Parry, JM Chemnitz, KA Frauwirth, AR Lanfranco, I Braunstein, ... Molecular and cellular biology 25 (21), 9543-9553, 2005 | 2259 | 2005 |
| The CD28 signaling pathway regulates glucose metabolism KA Frauwirth, JL Riley, MH Harris, RV Parry, JC Rathmell, DR Plas, ... Immunity 16 (6), 769-777, 2002 | 1623 | 2002 |
| SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T … JM Chemnitz, RV Parry, KE Nichols, CH June, JL Riley The Journal of Immunology 173 (2), 945-954, 2004 | 1527 | 2004 |
| Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases EE Perez, J Wang, JC Miller, Y Jouvenot, KA Kim, O Liu, N Wang, G Lee, ... Nature biotechnology 26 (7), 808-816, 2008 | 1379 | 2008 |
| Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo MC Milone, JD Fish, C Carpenito, RG Carroll, GK Binder, D Teachey, ... Molecular therapy 17 (8), 1453-1464, 2009 | 1376 | 2009 |
| Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains C Carpenito, MC Milone, R Hassan, JC Simonet, M Lakhal, MM Suhoski, ... Proceedings of the National Academy of Sciences 106 (9), 3360-3365, 2009 | 1022 | 2009 |
| Cutting edge: regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation EY Woo, H Yeh, CS Chu, K Schlienger, RG Carroll, JL Riley, LR Kaiser, ... The Journal of Immunology 168 (9), 4272-4276, 2002 | 991 | 2002 |
| PD‐1 signaling in primary T cells JL Riley Immunological reviews 229 (1), 114-125, 2009 | 979 | 2009 |
| Decade-long safety and function of retroviral-modified chimeric antigen receptor T cells J Scholler, TL Brady, G Binder-Scholl, WT Hwang, G Plesa, KM Hege, ... Science translational medicine 4 (132), 132ra53-132ra53, 2012 | 762 | 2012 |
| Identification of a titin-derived HLA-A1–presented peptide as a cross-reactive target for engineered MAGE A3–directed T cells BJ Cameron, AB Gerry, J Dukes, JV Harper, V Kannan, FC Bianchi, ... Science translational medicine 5 (197), 197ra103-197ra103, 2013 | 707 | 2013 |
| Ex vivo expansion of polyclonal and antigen-specific cytotoxic T lymphocytes by artificial APCs expressing ligands for the T-cell receptor, CD28 and 4-1BB MV Maus, AK Thomas, DGB Leonard, D Allman, K Addya, K Schlienger, ... Nature biotechnology 20 (2), 143-148, 2002 | 614 | 2002 |
| Expression of a functional CCR2 receptor enhances tumor localization and tumor eradication by retargeted human T cells expressing a mesothelin-specific chimeric antibody receptor EK Moon, C Carpenito, J Sun, LCS Wang, V Kapoor, J Predina, ... Clinical cancer research 17 (14), 4719-4730, 2011 | 557 | 2011 |
| Human T regulatory cell therapy: take a billion or so and call me in the morning JL Riley, CH June, BR Blazar Immunity 30 (5), 656-665, 2009 | 528 | 2009 |
| The PDL1-PD1 axis converts human TH1 cells into regulatory T cells S Amarnath, CW Mangus, JCM Wang, F Wei, A He, V Kapoor, JE Foley, ... Science translational medicine 3 (111), 111ra120-111ra120, 2011 | 517 | 2011 |
| FOXP3 interactions with histone acetyltransferase and class II histone deacetylases are required for repression B Li, A Samanta, X Song, KT Iacono, K Bembas, R Tao, S Basu, JL Riley, ... Proceedings of the National Academy of Sciences 104 (11), 4571-4576, 2007 | 481 | 2007 |
| Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8+ T cells B Youngblood, KJ Oestreich, SJ Ha, J Duraiswamy, RS Akondy, EE West, ... Immunity 35 (3), 400-412, 2011 | 447 | 2011 |
| DC-SIGN and DC-SIGNR bind ebola glycoproteins and enhance infection of macrophages and endothelial cells G Simmons, JD Reeves, CC Grogan, LH Vandenberghe, F Baribaud, ... Virology 305 (1), 115-123, 2003 | 446 | 2003 |
| The CD28 family: a T-cell rheostat for therapeutic control of T-cell activation JL Riley, CH June Blood 105 (1), 13-21, 2005 | 435 | 2005 |
| Multifactorial T-cell hypofunction that is reversible can limit the efficacy of chimeric antigen receptor–transduced human T cells in solid tumors EK Moon, LC Wang, DV Dolfi, CB Wilson, R Ranganathan, J Sun, ... Clinical cancer research 20 (16), 4262-4273, 2014 | 427 | 2014 |
| Massive ex vivo expansion of human natural regulatory T cells (Tregs) with minimal loss of in vivo functional activity KL Hippen, SC Merkel, DK Schirm, CM Sieben, D Sumstad, DM Kadidlo, ... Science translational medicine 3 (83), 83ra41-83ra41, 2011 | 408 | 2011 |
Bruce L LevineBarbara and Edward Netter Professor in Cancer Gene Therapy, Department of Pathology and LaboratoryVerified email at pennmedicine.upenn.edu
